Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 17, Issue 4, 2015, Pages 414-422

  Kelly, R P ^a   Garhyan, P ^b   Raddad, E ^b   Fu, H ^b   Lim, C N ^a   Prince, M J ^b   Pinaire, J A ^b   Loh, M T ^a   Deeg, M A ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetes care; Glucagon antagonist; Pharmacokinetics; Pharmacology

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C PEPTIDE; GLUCAGON; GLUCAGON RECEPTOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE RECEPTOR BLOCKING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LY 2409021; METFORMIN; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG; ADOMEGLIVANT; ANTIDIABETIC AGENT; BIPHENYL DERIVATIVE; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLUENZA; LETHARGY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PLASMA CONCENTRATION-TIME CURVE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SORE THROAT; SPONDYLOSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; YOUNG ADULT; ADVERSE EFFECTS; AGONISTS; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HALF LIFE TIME; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; RISK; SECRETION (PROCESS);

ADULT; AGED; BIPHENYL COMPOUNDS; COHORT STUDIES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON; HALF-LIFE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RECEPTORS, GLUCAGON; RISK; SINGLE-BLIND METHOD;

EID: 84924670428     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12446     Document Type: Article

References (26)

1. Aguilar-Parada E, Eisentraut AM, Unger RH. Effects of starvation on plasma pancreatic glucagon in normal man. Diabetes 1969; 18: 717-723.
2. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. N Engl J Med 1970; 283: 109-115.
3. Hollander PM, Asplin CM, Palmer JP. Glucose modulation of insulin and glucagon secretion in nondiabetic and diabetic man. Diabetes 1982; 31: 489-495.
4. Ward WK, Best JD, Halter JB, Porte D Jr. Prolonged infusion of somatostatin with glucagon replacement increases plasma glucose and glucose turnover in man. J Clin Endocrinol Metab 1984; 58: 449-453.
5. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007; 28: 253-283.
6. Gastaldelli A, Baldi S, Pettiti M et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 2000; 49: 1367-1373.
7. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 4053-4059.
8. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Jerich GE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.
9. Gastaldelli A, Miyazaki Y, Pettiti M et al. Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glucogenolysis. J Clin Endocrinol Metab 2004; 89: 3914-3921.
10. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 2002; 290: 839-843.
11. Vuguin PM, Charron MJ. Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models. Diabetes Obes Metab 2011; 13(Suppl. 1): 144-150.
12. Brand CL, Jorgensen PN, Svendsen I, Holst JJ. Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 1996; 45: 1076-1083.
13. Sloop KW, Cao X-C, Siesky AM. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 2004; 113: 1571-1581.
14. Gu W, Yan H, Winters A et al. Long-term inhibition of the glucacon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther 2009; 331: 871-881.
15. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011; 60: 391-397.
16. Mu J, Jiang G, Brady E et al. Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice. Diabetologia 2011; 54: 2381-2391.
17. Mu J, Qureshi SA, Brady EJ et al. Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist. PLoS One 2012; 7: e49572.
18. Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001; 44: 2018-2024.
19. Chappell J, Satonin, DK, Lam E, Tang C, Garhyan P. Effects of potent CYP inhibitors on the PK of LY2409021, a selective antagonist of the human glucagon receptor, and evaluation of QTc effects at supra-therapeutic exposures. AAPS Annual Meeting, San Diego, 2-6 November 2014.
20. Satonin DK, Chappell JC, Lam C etal. Pharmacokinetics of LY2409021, a glucagon receptor antagonist: metabolism, disposition and effect of food. Clin Pharmacol Ther 2013; 93(Suppl. 1): S105-106.
21. Gelling RW, Du XQ, Dichmann DS et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 2003; 100: 1438-1443.
22. Zhou C, Dhall D, Nissen NN, Chen CR, Yu R. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas 2009; 38: 941-946.
23. Whalley NM, Pritchard LE, Smith DM, White A. Processing of proglucagon to GLP-1 in pancreatic alpha-cells: is this a paracrine mechanism enabling GLP-1 to act on beta-cells? J Endocrinol 2011; 211: 99-106.
24. Conarello SL, Jiang G, Mu J et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 2007; 50: 142-150.
25. Longuet C, Sinclair EM, Maida A et al. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab 2008; 8: 359-371.
26. Liang Y, Osborne MC, Monia BP et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 2004; 53: 410-417.